The trial is taking place at:
V

VA Western New York Healthcare System | Research Department

Veeva-enabled site

Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices (LEOPARD)

Endologix logo

Endologix

Status

Active, not recruiting

Conditions

Abdominal Aortic Aneurysm

Treatments

Device: FDA Approved EVAR AAA Graft Systems
Device: AFX EVAR AAA Graft System

Study type

Interventional

Funder types

Industry

Identifiers

NCT02407457
CP-0011

Details and patient eligibility

About

The objective of this post-market trial is to evaluate Endologix AFX endovascular AAA system with anatomical fixation against other approved Endovascular systems with proximal fixation. Multiple U.S clinical centers will be involved in the trial to include a broad range of experience. Imaging data will be evaluated by an independent core lab.

Full description

This trial is a prospective, randomized, multi-center trial, intended to evaluate the outcomes of contemporary EVAR (Endovascular Aneurysm Repair) in a real world population. The trial is designed to compare the anatomically stabilized AFX Endograft System to a reference group of proximally fixated EVAR devices. Patients will be randomized between the two groups. Randomization will be 1:1. Each investigator will select one comparator device of their choice before enrolling the first patient. The study will sequentially evaluate non-inferiority and superiority hypotheses. Up to 80 sites with experience in EVAR and up to 800 subjects will participate in this study.

Enrollment

455 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female at least 18 years old
  • Subjects with minimum of 2 year life expectancy
  • Subjects have signed the informed consent document for data release
  • Subjects with infrarenal AAA who are assessed by the Investigator to be eligible for endovascular Abdominal Aortic Aneurysm Repair with the trial devices.

Exclusion criteria

  • Currently participating in another study where primary endpoint has not been reached yet
  • Known allergy to any of the device components
  • Pregnant (females of childbearing potential only)
  • Subjects with pre-existing EVAR, e.e. in need of repair/intervention of a previously failed EVAR

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

455 participants in 2 patient groups

AFX EVAR AAA Graft System
Active Comparator group
Description:
Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
Treatment:
Device: AFX EVAR AAA Graft System
FDA Approved EVAR AAA Graft Systems
Active Comparator group
Description:
Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
Treatment:
Device: FDA Approved EVAR AAA Graft Systems

Trial documents
1

Trial contacts and locations

56

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems